This new mandate builds upon and strengthens Azelis and Roquette’s global strategic partnership which spans multiple regions and industries.
Haleon will have a portfolio of category-leading brands including Sensodyne, Voltaren, Panadol and Centrum
The SureSTART consumables portfolio is designed for higher performance requirements, while meeting customer budgets
Enhertu is a HER2-directed antibody drug conjugate (ADC) being jointly developed by AstraZeneca and Daiichi Sankyo.
Data from the Phase 2b QUASAR Induction Study showed approximately 60% of patients achieved the primary endpoint of clinical response, and approximately 30% showed endoscopic improvement with TREMFYA treatment compared with placebo
Tepmetko is the first and only oral MET inhibitor to be approved in the European Economic Area for treating adult patients with advanced NSCLC harboring alterations leading to METex14 skipping, who require systemic therapy following prior treatment
Launches a host of innovative products & solutions across the entire flexible packaging value chain in October - December 2021
Monitoring results demonstrated a good safety profile of the combination. No serious adverse events related to vaccination were registered
Rimegepant is the first oral calcitonin gene-related peptide receptor antagonist to demonstrate positive results in a pivotal trial in the Asia Pacific
Twist will leverage C2i’s leadership in whole-genome cancer signatures across solid cancers to generate unique synthetic reference materials for cancer detection validation in labs across the globe
Subscribe To Our Newsletter & Stay Updated
